RecAP Therapy for Renal Function Preservation in Sepsis-Associated AKI
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacologic interventions are lacking for preventing or treating sepsis-associated acute kidney injury (SA-AKI), which is a common and severe complication in intensive care units, associated with high mortality and risk of chronic kidney disease.
Innovation Solution
Administration of recombinant alkaline phosphatase (RecAP) in doses of 500 U/kg to 2,000 U/kg, particularly in subjects with moderate to severe kidney injury, as determined by creatinine clearance or estimated glomerular filtration rate, to enhance renal function and reduce the duration of renal replacement therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no pharmacologic intervention is administered, then the treatment approach remains simple, but renal function deteriorates and mortality increases in sepsis-associated AKI patients
Solution Approach 1:
The patent applies parameter changes by administering alkaline phosphatase enzyme at specific dosages (500-2000 U/kg) to alter the biochemical parameters in sepsis-associated AKI patients. This enzymatic intervention changes the metabolic state by reducing inflammatory markers and improving renal hemodynamics, thereby preserving renal function without requiring complex mechanical support systems
Solution Approach 2:
Alkaline phosphatase serves as a biochemical intermediary that mediates between the harmful sepsis environment and the vulnerable kidney tissue. The enzyme acts as a protective agent that neutralizes toxic effects through its catalytic activity, reducing inflammatory mediators and protecting renal cells from damage while maintaining physiological function
2Reliability
If early pharmacologic treatment is initiated, then renal function improvement is achieved, but the risk of treatment side effects and costs increases
Solution Approach 1:
The patent implements preliminary action by initiating alkaline phosphatase treatment early in the course of sepsis-associated AKI, before irreversible renal damage occurs. This timely intervention prevents the progression to severe kidney failure and reduces the need for subsequent complex treatments like dialysis, thereby improving outcomes while minimizing exposure to long-term treatment risks
Solution Approach 2:
The treatment uses a relatively simple, short-acting enzymatic therapy that can be administered as a temporary intervention. The alkaline phosphatase provides acute protection during the critical early phase of AKI, after which its effects diminish, but by this time renal function has already been stabilized, avoiding the need for long-term complex therapies
Data Source
AI summary
The present disclosure relates to the use of alkaline phosphatases, and in particular improved alkaline phosphatases such as RecAP, for the prevention, treatment, cure, or amelioration of the symptoms of acute kidney injury caused, e.g., by sepsis. The application relates to methods of preserving renal function renal function, shortening the duration of renal replacement therapy, increasing the creatinine clearance, decreasing the risk of death in subjects with sepsis-associate acute kidney injury (SA-AKI) or at risk of SA-AKI.